• Prosecuting a patent portfolio and providing patent strategy advice for a French pharmaceutical company whose drug product, a combination of three known small molecule drugs, is in Phase 3 clinical trials for a rare genetic disease.
    • Drafting, filing, and prosecuting patent applications covering new uses and formulations of legacy in-licensed lead compound as well as new composition of matter applications for drug discovery program on behalf of Cambridge, Massachusetts-based pharmaceutical company.
    • Diligence evaluation of a US pharmaceutical company’s patent estate covering a cystic fibrosis small molecule drug candidate in the company’s US$88 million IPO.
    • Diligence evaluation of multiple patent estates covering small molecule drug candidates on behalf of a European pharmaceutical company in its US$275 million IPO.

    Includes matters handled at Dechert or prior to joining the firm.

    • University of Notre Dame, B.S., Chemistry, 2004, cum laude
    • Boston College, Ph.D., Organic Chemistry, 2010
    • Suffolk University Law School, J.D., Intellectual Property Concentration, 2018
    • Massachusetts
    • United States Patent and Trademark Office
    • English
    • Spanish
    • American Bar Association
    • American Intellectual Property Association